person · Reporting owner

Tansey Casey M

Disclosed activity across 12 companies

Tapewire entity: 21218
SEC CIK: 0001474322

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CARLSMED, INC.CARL · Entity 5551	10% owner	July 24, 2025	September 15, 2026
Heartflow, Inc.HTFL · Entity 3993	Director	June 16, 2026	June 18, 2026
Inspire Medical Systems, Inc.INSP · Entity 1186	Director	July 15, 2026	July 18, 2026
Intersect ENT, Inc.XENT · Entity 127294	Director	June 01, 2017	June 05, 2017
Mobia Medical, Inc.MOBI · Entity 5669	Director	August 18, 2026	August 21, 2026
SHOULDER INNOVATIONS, INC.SI · Entity 5607	Director · 10% owner	October 05, 2026	October 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CARLSMED, INC.

Report date July 24, 2025 · Filed September 15, 2026 · Amendment

Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	200,000	Reported balance After 2025-07-24 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2025-07-24 · Purchase · Acquired 200,000 · Balance 200,000 F1: Stock held by Casey M. Tansey.

Filing footnotes · ownership attribution and instrument terms

F1: Stock held by Casey M. Tansey.

Heartflow, Inc.

Report date June 16, 2026 · Filed June 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $32.05 · Expires 2036-06-16	Direct	16,075	Reported balance After 2026-06-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-16 · Grant · Acquired 16,075 · Balance 16,075 F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in full on the earlier of the day prior to Heartflow's annual meeting of shareholders in 2027 and the first anniversary of the grant date, subject to continued service through such date.

Inspire Medical Systems, Inc.

Report date July 15, 2026 · Filed July 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	26,632	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 346 · Balance 26,632 F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.
Common StockSEC Table I · non-derivative	IndirectBy Family Trust	500	Reported balance Holding disclosure · report date 2026-07-15 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 500 F2: Securities held by The Kimberly Tansey Irrevocable Trust.
Common StockSEC Table I · non-derivative	IndirectBy Family Trust	500	Reported balance Holding disclosure · report date 2026-07-15 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 500 F3: Securities held by The Kylie Tansey Irrevocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock received in lieu of cash fees pursuant to the Company's Non-Employee Director Compensation Policy.

F2: Securities held by The Kimberly Tansey Irrevocable Trust.

F3: Securities held by The Kylie Tansey Irrevocable Trust.

Intersect ENT, Inc.

Report date June 01, 2017 · Filed June 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,546	Reported balance After 2017-06-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2017-06-01 · Grant · Acquired 2,546 · Balance 2,546 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31	Direct	6,035	Reported balance After 2017-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-06-01 · Grant · Acquired 6,035 · Balance 6,035 F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018.

F2: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017.

Mobia Medical, Inc.

Report date August 18, 2026 · Filed August 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	318,332	Reported balance After 2026-08-18 transaction · row 1 1 source row Row 1 · 2026-08-18 · Purchase · Acquired 16,441 · Balance 318,332 F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $11.90 to $12.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SHOULDER INNOVATIONS, INC.

Report date October 05, 2026 · Filed October 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	53,445	Reported balance After 2026-10-05 transaction · row 1 1 source row Row 1 · 2026-10-05 · Grant · Acquired 733 · Balance 53,445 F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.
Common StockSEC Table I · non-derivative	IndirectHeld by U.S. Venture Partners XII, L.P.	1,686,403	Reported balance Holding disclosure · report date 2026-10-05 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,686,403 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.
Common StockSEC Table I · non-derivative	IndirectHeld by U.S. Venture Partners XII-A, L.P.	85,586	Reported balance Holding disclosure · report date 2026-10-05 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 85,586 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.
Common StockSEC Table I · non-derivative	IndirectHeld by U.S. Venture Partners Select Fund I, L.P.	921,130	Reported balance Holding disclosure · report date 2026-10-05 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 921,130 F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units ("RSUs") received in lieu of cash retainer fees, which were fully vested as of the grant date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. The Reporting Person voluntarily elected to defer receipt of the Common Stock issuable upon settlement of the RSUs until the Reporting Person's departure from the Board of Directors.

F2: Presidio Management Group XII, L.L.C. ("PMG XII") is the general partner of U.S. Venture Partners XII, L.P. ("USVP XII") and U.S. Venture Partners XII-A, L.P. ("USVP XII-A") and has sole voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Steven M. Krausz, Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG XII, and share voting and dispositive power with respect to the shares held by USVP XII and USVP XII-A. Casey M. Tansey is the managing partner of PMG XII and may be deemed to share voting and dispositive power over the reported securities held by USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C. ("PMG Select") is the general partner of U.S. Venture Partners Select Fund I, L.P. ("USVP SFI"), and U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A") and has sole voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A.

F3: Richard W. Lewis, Jonathan D. Root and Dafina Toncheva are the managing members of PMG Select and share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Casey M. Tansey, a member of the Issuer's board of directors, is the managing partner of PMG Select and may be deemed to share voting and dispositive power with respect to the shares held by USVP SFI on its own behalf and as nominee for USVP SFI-A. Each of the managing members and managing partner of PMG XII and PMG Select disclaims beneficial ownership of such holdings, except to the extent of their pecuniary interest in the shares.

Past disclosures · reporting ended (6)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARS Pharmaceuticals, Inc.

Report date December 08, 2020 · Filed December 09, 2020

Jointly reported with Presidio Management Group XII, L.L.C., U.S. Venture Partners XII, L.P., U.S. Venture Partners XII-A, L.P.

Section 16 reporting ended · disclosed 2020-12-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy U.S. Venture Partners XII, L.P.	2,069,167	Last balance in matching sequence After 2020-12-08 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-12-08 · Conversion · Acquired 1,779,969 · Balance 1,779,969 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 2 · 2020-12-08 · Conversion · Acquired 289,198 · Balance 2,069,167 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectBy U.S. Venture Partners XII-A, L.P.	105,012	Last balance in matching sequence After 2020-12-08 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 3 · 2020-12-08 · Conversion · Acquired 90,335 · Balance 90,335 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2020-12-08 · Conversion · Acquired 14,677 · Balance 105,012 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Tansey	47,619	Reported balance After 2020-12-08 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2020-12-08 · Purchase · Acquired 47,619 · Balance 47,619 F1: The shares were purchased in the Issuer's initial public offering.
Preferred Series B StockSEC Table II · derivative / convertible security	IndirectBy U.S. Venture Partners XII, L.P.	0	Reported balance After 2020-12-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-12-08 · Conversion · Disposed 6,609,027 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Preferred Series B StockSEC Table II · derivative / convertible security	IndirectBy U.S. Venture Partners XII-A, L.P.	0	Reported balance After 2020-12-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-12-08 · Conversion · Disposed 335,417 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Preferred Series C StockSEC Table II · derivative / convertible security	IndirectBy U.S. Venture Partners XII, L.P.	0	Reported balance After 2020-12-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-12-08 · Conversion · Disposed 1,073,793 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Preferred Series C StockSEC Table II · derivative / convertible security	IndirectBy U.S. Venture Partners XII-A, L.P.	0	Reported balance After 2020-12-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-12-08 · Conversion · Disposed 54,496 · Balance 0 F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date. F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were purchased in the Issuer's initial public offering.

F2: Series B and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock immediately upon the closing of the Issuer's imitial public offering, for no additional consideration at a rate of 1 share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock had no expiration date.

F3: Presidio Management Group XII, L.L.C. ("PMG XII"), the general partner of each of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, the "USVP XII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP XII. Casey Tansey is the sole managing partner of PMG XII and may be deemed to have voting and dispositive power over the reported securities held by the USVP XII Funds, and each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

BOX INC

Report date June 02, 2017 · Filed June 08, 2017 · Amendment

Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, LIDDLE DAVID E, Matteucci Paul A, ROOT JONATHAN D, YOUNG PHILIP M

Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP IX	0	Last balance in matching sequence After 2017-06-02 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2: Prorata distribution in kind from the partnership without consideration to its limited partners. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Class B Common StockSEC Table II · derivative / convertible security	IndirectDirectly owned by USVP IX	3,713,775	Reported balance After 2017-06-02 transaction · row 3 Amendment: may correct only part of an earlier disclosure. 1 source row Row 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

F2: Prorata distribution in kind from the partnership without consideration to its limited partners.

F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

INTERMOLECULAR INC

Report date November 08, 2018 · Filed November 13, 2018

Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, ROOT JONATHAN D, YOUNG PHILIP M

Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by USVP IX	0	Reported balance After 2018-11-08 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	Direct	856,155	Reported balance After 2018-11-08 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
Common Stock, $0.001 per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2018-11-08 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Steven Krausz	97,593	Last balance in matching sequence After 2018-11-13 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593 F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by David Liddle	69,609	Reported balance After 2018-11-08 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Paul Matteucci	60,408	Reported balance After 2018-11-08 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Jonathan Root	85,851	Reported balance After 2018-11-08 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Casey Tansey	60,336	Reported balance After 2018-11-08 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
Common Stock, $0.001 per shareSEC Table I · non-derivative	IndirectDirectly owned by Philip Young	82,370	Reported balance After 2018-11-08 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.

F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Inari Medical, Inc.

Report date March 16, 2021 · Filed March 18, 2021

Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP

Section 16 reporting ended · disclosed 2021-03-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP X	2,619,872	Reported balance After 2021-03-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-03-16 · Other · Disposed 2,619,872 · Balance 2,619,872 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by AFF X	83,813	Reported balance After 2021-03-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-03-16 · Other · Disposed 83,814 · Balance 83,813 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by PMG X.	685,827	Reported balance After 2021-03-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-03-16 · Other · Acquired 685,827 · Balance 685,827 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by PMG X.	0	Reported balance After 2021-03-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-03-16 · Other · Disposed 685,827 · Balance 0 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Tansey	242,988	Reported balance After 2021-03-16 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-03-16 · Other · Acquired 77,296 · Balance 242,988 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable.

F2: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F3: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP Funds, without additional consideration. Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F4: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration, to its members (the "PMG X Distribution"). Casey Tansey is the sole managing partner of PMG X and may be deemed to have shared voting and sole dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

F5: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution.

ON24 INC.

Report date August 17, 2021 · Filed August 19, 2021

Jointly reported with PRESIDIO MANAGEMENT GROUP VII L L C, US VENTURE PARTNERS VII L P, 2180 ASSOCIATES FUND VII L P, USVP ENTREPRENEUR PARTNERS VII A L P, USVP ENTREPRENEUR PARTNERS VII B L P

Section 16 reporting ended · disclosed 2021-08-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP VII	4,368,405	Reported balance After 2021-08-17 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-08-17 · Other · Disposed 1,500,000 · Balance 4,368,405 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein
Common StockSEC Table I · non-derivative	IndirectDirectly owned by 2180-VII	91,008	Reported balance After 2021-08-17 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2021-08-17 · Other · Disposed 31,250 · Balance 91,008 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein
Common StockSEC Table I · non-derivative	Direct	312	Reported balance After 2021-08-17 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2021-08-17 · Other · Acquired 312 · Balance 312 F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-08-18 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-08-18 · Sale · Disposed 312 · Balance 0 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by EP7-A	45,505	Reported balance After 2021-08-18 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein
Common StockSEC Table I · non-derivative	IndirectDirectly owned by EP7-B	45,505	Reported balance After 2021-08-18 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2021-08-18 · Sale · Disposed 15,625 · Balance 45,505 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein
Common StockSEC Table I · non-derivative	IndirectDirectly owned by Casey Tansey	5,000	Reported balance Holding disclosure · report date 2021-08-17 · row 7 Holding and transaction disclosures are not merged. 1 source row Row 7 · Balance 5,000 F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners VII, L.P. ("USVP VII") and 2180 Associates Fund VII, L.P. ("2180-VII'), without additional consideration to its partners or members. Presidio Management Group VII, L.L.C. ("PMG VII") received a pro-rata in-kind distribution from 2180-VII.

F2: Presidio Management Group VII, L.L.C. ("PMG VII"), the general partner of each of U.S. Venture Partners VII, L.P. ("USVP VII"), 2180 Associates Fund VII, L.P. ("2180-VII), USVP Entrepreneur Partners VII-A, L.P. ("EP7-A") and USVP Entrepreneur Partners VII-B, L.P. ("EP7-B") (together, the "USVP VII Funds"), has sole voting and dispositive power with respect to the shares held by the USVP VII Funds. Casey Tansey is the sole managing partner of PMG VII and may be deemed to have sole dispositive power over the reported securities held by the USVP VII Funds and may be deemed to have shared voting power over the reported securities held by the USVP VII Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.45 to $20.50 inclusive for sales on 8/18/2021. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

eFFECTOR Therapeutics, Inc.

Report date August 01, 2022 · Filed August 03, 2022

Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, ROOT JONATHAN D

Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectDirectly owned by USVP X	3,981,940	Last balance in matching sequence After 2022-08-03 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectDirectly owned by AFF X	127,569	Last balance in matching sequence After 2022-08-03 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 27, 2022 Filed Jul 27, 2022 22:20 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	42,344	$0.89	$37,770.85	Disclosure SEC source: 0001062993-22-016802 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,124,297 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.91 to $0.95, inclusive for sales on 7/25/22; prices ranging from $0.90 to $0.91, inclusive for sales on 7/26/22; and prices ranging from $0.89 to $0.91, inclusive for sales on 7/27/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 26, 2022 Filed Jul 27, 2022 22:20 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	84	$0.90	$75.94	Disclosure SEC source: 0001062993-22-016802 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 133,330 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.91 to $0.95, inclusive for sales on 7/25/22; prices ranging from $0.90 to $0.91, inclusive for sales on 7/26/22; and prices ranging from $0.89 to $0.91, inclusive for sales on 7/27/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 26, 2022 Filed Jul 27, 2022 22:20 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	2,691	$0.90	$2,432.66	Disclosure SEC source: 0001062993-22-016802 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,166,641 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.91 to $0.95, inclusive for sales on 7/25/22; prices ranging from $0.90 to $0.91, inclusive for sales on 7/26/22; and prices ranging from $0.89 to $0.91, inclusive for sales on 7/27/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 25, 2022 Filed Jul 27, 2022 22:20 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	69	$0.93	$64.24	Disclosure SEC source: 0001062993-22-016802 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 133,414 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.91 to $0.95, inclusive for sales on 7/25/22; prices ranging from $0.90 to $0.91, inclusive for sales on 7/26/22; and prices ranging from $0.89 to $0.91, inclusive for sales on 7/27/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 25, 2022 Filed Jul 27, 2022 22:20 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	2,210	$0.93	$2,057.51	Disclosure SEC source: 0001062993-22-016802 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,169,332 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.91 to $0.95, inclusive for sales on 7/25/22; prices ranging from $0.90 to $0.91, inclusive for sales on 7/26/22; and prices ranging from $0.89 to $0.91, inclusive for sales on 7/27/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 22, 2022 Filed Jul 22, 2022 22:03 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	231	$0.91	$210.44	Disclosure SEC source: 0001062993-22-016678 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 133,483 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive for sales on 7/20/22; prices ranging from $0.94 to $1.00, inclusive for sales on 7/21/22; and prices ranging from $0.91 to $0.94, inclusive for sales on 7/22/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 22, 2022 Filed Jul 22, 2022 22:03 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	7,383	$0.91	$6,718.53	Disclosure SEC source: 0001062993-22-016678 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,171,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive for sales on 7/20/22; prices ranging from $0.94 to $1.00, inclusive for sales on 7/21/22; and prices ranging from $0.91 to $0.94, inclusive for sales on 7/22/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 21, 2022 Filed Jul 22, 2022 22:03 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	81	$0.96	$77.44	Disclosure SEC source: 0001062993-22-016678 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 133,714 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive for sales on 7/20/22; prices ranging from $0.94 to $1.00, inclusive for sales on 7/21/22; and prices ranging from $0.91 to $0.94, inclusive for sales on 7/22/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 21, 2022 Filed Jul 22, 2022 22:03 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	2,584	$0.96	$2,467.72	Disclosure SEC source: 0001062993-22-016678 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,178,925 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive for sales on 7/20/22; prices ranging from $0.94 to $1.00, inclusive for sales on 7/21/22; and prices ranging from $0.91 to $0.94, inclusive for sales on 7/22/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 20, 2022 Filed Jul 22, 2022 22:03 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	304	$1.00	$304.30	Disclosure SEC source: 0001062993-22-016678 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 133,795 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive for sales on 7/20/22; prices ranging from $0.94 to $1.00, inclusive for sales on 7/21/22; and prices ranging from $0.91 to $0.94, inclusive for sales on 7/22/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 20, 2022 Filed Jul 22, 2022 22:03 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	9,726	$1.00	$9,735.73	Disclosure SEC source: 0001062993-22-016678 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,181,509 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.00 to $1.02, inclusive for sales on 7/20/22; prices ranging from $0.94 to $1.00, inclusive for sales on 7/21/22; and prices ranging from $0.91 to $0.94, inclusive for sales on 7/22/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 19, 2022 Filed Jul 19, 2022 20:54 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	84	$1.00	$84.00	Disclosure SEC source: 0001062993-22-016514 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 134,099 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.14, inclusive for sales on 7/15/22; prices ranging from $1.00 to $1.15, inclusive for sales on 7/18/22; and prices ranging from $1.00 to $1.00, inclusive for sales on 7/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 19, 2022 Filed Jul 19, 2022 20:54 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	2,670	$1.00	$2,670.00	Disclosure SEC source: 0001062993-22-016514 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,191,235 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.14, inclusive for sales on 7/15/22; prices ranging from $1.00 to $1.15, inclusive for sales on 7/18/22; and prices ranging from $1.00 to $1.00, inclusive for sales on 7/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 18, 2022 Filed Jul 19, 2022 20:54 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	635	$1.08	$686.44	Disclosure SEC source: 0001062993-22-016514 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 134,183 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.14, inclusive for sales on 7/15/22; prices ranging from $1.00 to $1.15, inclusive for sales on 7/18/22; and prices ranging from $1.00 to $1.00, inclusive for sales on 7/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 18, 2022 Filed Jul 19, 2022 20:54 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	20,352	$1.08	$21,980.16	Disclosure SEC source: 0001062993-22-016514 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,193,905 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.14, inclusive for sales on 7/15/22; prices ranging from $1.00 to $1.15, inclusive for sales on 7/18/22; and prices ranging from $1.00 to $1.00, inclusive for sales on 7/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 15, 2022 Filed Jul 19, 2022 20:54 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	1,423	$1.11	$1,576.68	Disclosure SEC source: 0001062993-22-016514 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 134,818 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.14, inclusive for sales on 7/15/22; prices ranging from $1.00 to $1.15, inclusive for sales on 7/18/22; and prices ranging from $1.00 to $1.00, inclusive for sales on 7/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 15, 2022 Filed Jul 19, 2022 20:54 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	44,477	$1.11	$49,280.52	Disclosure SEC source: 0001062993-22-016514 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,214,257 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.10 to $1.14, inclusive for sales on 7/15/22; prices ranging from $1.00 to $1.15, inclusive for sales on 7/18/22; and prices ranging from $1.00 to $1.00, inclusive for sales on 7/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
July 11, 2022 Filed Jul 13, 2022 22:09 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	77	$193.86	$14,927.22	Disclosure SEC source: 0001104659-22-079608 · tm2221003-2_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,410 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document
May 19, 2022 Filed May 19, 2022 22:16 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	266	$1.69	$449.27	Disclosure SEC source: 0001062993-22-013050 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 136,241 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.82, inclusive for sales on 5/17/22; prices ranging from $1.70 to $1.93, inclusive for sales on 5/18/22; and prices ranging from $1.63 to $1.78, inclusive for sales on 5/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 19, 2022 Filed May 19, 2022 22:16 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	8,308	$1.69	$14,040.52	Disclosure SEC source: 0001062993-22-013050 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,258,734 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.82, inclusive for sales on 5/17/22; prices ranging from $1.70 to $1.93, inclusive for sales on 5/18/22; and prices ranging from $1.63 to $1.78, inclusive for sales on 5/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 18, 2022 Filed May 19, 2022 22:16 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	437	$1.73	$757.76	Disclosure SEC source: 0001062993-22-013050 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 136,507 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.82, inclusive for sales on 5/17/22; prices ranging from $1.70 to $1.93, inclusive for sales on 5/18/22; and prices ranging from $1.63 to $1.78, inclusive for sales on 5/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 18, 2022 Filed May 19, 2022 22:16 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	13,649	$1.73	$23,667.37	Disclosure SEC source: 0001062993-22-013050 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,267,042 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.82, inclusive for sales on 5/17/22; prices ranging from $1.70 to $1.93, inclusive for sales on 5/18/22; and prices ranging from $1.63 to $1.78, inclusive for sales on 5/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 17, 2022 Filed May 19, 2022 22:16 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	365	$1.75	$638.75	Disclosure SEC source: 0001062993-22-013050 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 136,944 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.82, inclusive for sales on 5/17/22; prices ranging from $1.70 to $1.93, inclusive for sales on 5/18/22; and prices ranging from $1.63 to $1.78, inclusive for sales on 5/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 17, 2022 Filed May 19, 2022 22:16 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	11,402	$1.75	$19,942.10	Disclosure SEC source: 0001062993-22-013050 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,280,691 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.82, inclusive for sales on 5/17/22; prices ranging from $1.70 to $1.93, inclusive for sales on 5/18/22; and prices ranging from $1.63 to $1.78, inclusive for sales on 5/19/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 16, 2022 Filed May 16, 2022 22:36 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	395	$1.75	$689.67	Disclosure SEC source: 0001062993-22-012659 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 137,309 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.02, inclusive for sales on 5/12/22; prices ranging from $1.80 to $1.97, inclusive for sales on 5/13/22; and prices ranging from $1.65 to $1.80, inclusive for sales on 5/16/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 16, 2022 Filed May 16, 2022 22:36 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	12,374	$1.75	$21,605.00	Disclosure SEC source: 0001062993-22-012659 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,292,093 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.02, inclusive for sales on 5/12/22; prices ranging from $1.80 to $1.97, inclusive for sales on 5/13/22; and prices ranging from $1.65 to $1.80, inclusive for sales on 5/16/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 13, 2022 Filed May 16, 2022 22:36 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	701	$1.84	$1,289.14	Disclosure SEC source: 0001062993-22-012659 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 137,704 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.02, inclusive for sales on 5/12/22; prices ranging from $1.80 to $1.97, inclusive for sales on 5/13/22; and prices ranging from $1.65 to $1.80, inclusive for sales on 5/16/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 13, 2022 Filed May 16, 2022 22:36 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	21,906	$1.84	$40,285.13	Disclosure SEC source: 0001062993-22-012659 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,304,467 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.02, inclusive for sales on 5/12/22; prices ranging from $1.80 to $1.97, inclusive for sales on 5/13/22; and prices ranging from $1.65 to $1.80, inclusive for sales on 5/16/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 12, 2022 Filed May 16, 2022 22:36 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	336	$2.00	$673.01	Disclosure SEC source: 0001062993-22-012659 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 138,405 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.02, inclusive for sales on 5/12/22; prices ranging from $1.80 to $1.97, inclusive for sales on 5/13/22; and prices ranging from $1.65 to $1.80, inclusive for sales on 5/16/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 12, 2022 Filed May 16, 2022 22:36 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	10,464	$2.00	$20,959.39	Disclosure SEC source: 0001062993-22-012659 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,326,373 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.98 to $2.02, inclusive for sales on 5/12/22; prices ranging from $1.80 to $1.97, inclusive for sales on 5/13/22; and prices ranging from $1.65 to $1.80, inclusive for sales on 5/16/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 11, 2022 Filed May 12, 2022 00:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	155	$2.35	$363.63	Disclosure SEC source: 0001062993-22-012169 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 138,741 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.61, inclusive for sales on 5/9/22; prices ranging from $2.40 to $2.45, inclusive for sales on 5/10/22; and prices ranging from $2.14 to $2.40, inclusive for sales on 5/11/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 11, 2022 Filed May 12, 2022 00:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	4,845	$2.35	$11,361.53	Disclosure SEC source: 0001062993-22-012169 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,336,837 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.61, inclusive for sales on 5/9/22; prices ranging from $2.40 to $2.45, inclusive for sales on 5/10/22; and prices ranging from $2.14 to $2.40, inclusive for sales on 5/11/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 10, 2022 Filed May 12, 2022 00:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	1,241	$2.41	$2,994.53	Disclosure SEC source: 0001062993-22-012169 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 138,896 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.61, inclusive for sales on 5/9/22; prices ranging from $2.40 to $2.45, inclusive for sales on 5/10/22; and prices ranging from $2.14 to $2.40, inclusive for sales on 5/11/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 10, 2022 Filed May 12, 2022 00:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	38,743	$2.41	$93,486.86	Disclosure SEC source: 0001062993-22-012169 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,341,682 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.61, inclusive for sales on 5/9/22; prices ranging from $2.40 to $2.45, inclusive for sales on 5/10/22; and prices ranging from $2.14 to $2.40, inclusive for sales on 5/11/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 09, 2022 Filed May 12, 2022 00:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	124	$2.54	$314.59	Disclosure SEC source: 0001062993-22-012169 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 140,137 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.61, inclusive for sales on 5/9/22; prices ranging from $2.40 to $2.45, inclusive for sales on 5/10/22; and prices ranging from $2.14 to $2.40, inclusive for sales on 5/11/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
May 09, 2022 Filed May 12, 2022 00:10 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	3,876	$2.54	$9,829.54	Disclosure SEC source: 0001062993-22-012169 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,380,425 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.61, inclusive for sales on 5/9/22; prices ranging from $2.40 to $2.45, inclusive for sales on 5/10/22; and prices ranging from $2.14 to $2.40, inclusive for sales on 5/11/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
April 28, 2022 Filed May 11, 2022 00:48 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantStock Option (right to buy) · Derivative	1,243	$0.00 Strike: $211.29	$0.00	Disclosure SEC source: 0001104659-22-058417 · tm2215111-4_4seq1.xml · derivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,243 Underlying: Common Stock · 1,243 shares Expires 2032-04-28 F1 · derivative.exercise_date: The option vests and becomes exercisable on April 28, 2023, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document
April 08, 2022 Filed Apr 13, 2022 00:46 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	59	$254.08	$14,990.72	Disclosure SEC source: 0001104659-22-045210 · tm2212578-4_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,333 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document
January 10, 2022 Filed Jan 12, 2022 21:15 UTC	Inspire Medical Systems, Inc. INSP · Entity 1186	GrantCommon Stock	65	$227.56	$14,791.40	Disclosure SEC source: 0001104659-22-003597 · tm222681-1_4seq1.xml · nonDerivative · entry 1 Tansey Casey M · CIK 0001474322 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,274 F1 · shares: Represents shares of common stock received in lieu of cash fees pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document
December 02, 2021 Filed Dec 7, 2021 00:27 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	252	$5.68	$1,431.36	Disclosure SEC source: 0001062993-21-012276 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 140,261 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.86, inclusive for sales on 12/2/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
December 02, 2021 Filed Dec 7, 2021 00:27 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	7,861	$5.68	$44,650.48	Disclosure SEC source: 0001062993-21-012276 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,384,301 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.50 to $5.86, inclusive for sales on 12/2/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
December 01, 2021 Filed Dec 1, 2021 23:31 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	597	$6.44	$3,842.89	Disclosure SEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 140,513 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
December 01, 2021 Filed Dec 1, 2021 23:31 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	18,648	$6.44	$120,037.18	Disclosure SEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,392,162 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 30, 2021 Filed Dec 1, 2021 23:31 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	850	$6.53	$5,553.05	Disclosure SEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 141,110 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 30, 2021 Filed Dec 1, 2021 23:31 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	26,559	$6.53	$173,483.39	Disclosure SEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 3 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,410,810 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 29, 2021 Filed Dec 1, 2021 23:31 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	799	$6.70	$5,349.31	Disclosure SEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 2 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 141,960 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 29, 2021 Filed Dec 1, 2021 23:31 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	24,965	$6.70	$167,140.68	Disclosure SEC source: 0001062993-21-011920 · form4.xml · nonDerivative · entry 1 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,437,369 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.65 to $6.83, inclusive for sales on 11/29/21; prices ranging from $6.13 to $6.90, inclusive for sales on 11/30/21; prices ranging from $6.04 to $6.83, inclusive for sales on 12/1/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 26, 2021 Filed Nov 26, 2021 21:43 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	156	$7.01	$1,093.25	Disclosure SEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 6 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 142,759 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 26, 2021 Filed Nov 26, 2021 21:43 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	4,870	$7.01	$34,148.44	Disclosure SEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 5 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 4,462,334 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document
November 24, 2021 Filed Nov 26, 2021 21:43 UTC	eFFECTOR Therapeutics, Inc. EFTR · Entity 89916	SaleCommon Stock	1,132	$7.36	$8,325.86	Disclosure SEC source: 0001062993-21-011704 · form4.xml · nonDerivative · entry 4 Presidio Management Group X LLC · CIK 0001602744 · 10% owner US VENTURE PARTNERS X LP · CIK 0001440514 · 10% owner USVP X AFFILIATES LP · CIK 0001453359 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 142,915 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.63, inclusive for sales on 11/23/21; prices ranging from $7.25 to $7.48, inclusive for sales on 11/24/21; prices ranging from $6.75 to $7.34, inclusive for sales on 11/26/21. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.